158 related articles for article (PubMed ID: 34052717)
1. Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia.
Puxeddu M; Shen H; Bai R; Coluccia A; Bufano M; Nalli M; Sebastiani J; Brancaccio D; Da Pozzo E; Tremolanti C; Martini C; Orlando V; Biagioni S; Sinicropi MS; Ceramella J; Iacopetta D; Coluccia AML; Hamel E; Liu T; Silvestri R; La Regina G
Eur J Med Chem; 2021 Oct; 221():113532. PubMed ID: 34052717
[TBL] [Abstract][Full Text] [Related]
2. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
[TBL] [Abstract][Full Text] [Related]
3. New 6- and 7-heterocyclyl-1H-indole derivatives as potent tubulin assembly and cancer cell growth inhibitors.
La Regina G; Bai R; Coluccia A; Naccarato V; Famiglini V; Nalli M; Masci D; Verrico A; Rovella P; Mazzoccoli C; Da Pozzo E; Cavallini C; Martini C; Vultaggio S; Dondio G; Varasi M; Mercurio C; Hamel E; Lavia P; Silvestri R
Eur J Med Chem; 2018 May; 152():283-297. PubMed ID: 29730191
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Evaluation of in Vitro and in Vivo Anticancer Activity of 4-Substituted Coumarins: A Novel Class of Potent Tubulin Polymerization Inhibitors.
Cao D; Liu Y; Yan W; Wang C; Bai P; Wang T; Tang M; Wang X; Yang Z; Ma B; Ma L; Lei L; Wang F; Xu B; Zhou Y; Yang T; Chen L
J Med Chem; 2016 Jun; 59(12):5721-39. PubMed ID: 27213819
[TBL] [Abstract][Full Text] [Related]
5. Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
Lin S; Liang Y; Cheng J; Pan F; Wang Y
Eur J Med Chem; 2021 Mar; 214():113256. PubMed ID: 33581556
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Wang Y; Sun M; Wang Y; Qin J; Zhang Y; Pang Y; Yao Y; Yang H; Duan Y
Eur J Med Chem; 2021 Dec; 225():113790. PubMed ID: 34454126
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
Wang G; Li C; He L; Lei K; Wang F; Pu Y; Yang Z; Cao D; Ma L; Chen J; Sang Y; Liang X; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2014 Apr; 22(7):2060-79. PubMed ID: 24629450
[TBL] [Abstract][Full Text] [Related]
8. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel benzodiazepine derivatives as anticancer agents through inhibition of tubulin polymerization in vitro and in vivo.
Pang Y; Lin H; Ou C; Cao Y; An B; Yan J; Li X
Eur J Med Chem; 2019 Nov; 182():111670. PubMed ID: 31499359
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.
Penthala NR; Zong H; Ketkar A; Madadi NR; Janganati V; Eoff RL; Guzman ML; Crooks PA
Eur J Med Chem; 2015 Mar; 92():212-20. PubMed ID: 25557492
[TBL] [Abstract][Full Text] [Related]
12. The discovery of novel indazole derivatives as tubulin colchicine site binding agents that displayed potent antitumor activity both in vitro and in vivo.
Cui YJ; Ma CC; Zhang CM; Tang LQ; Liu ZP
Eur J Med Chem; 2020 Feb; 187():111968. PubMed ID: 31865012
[TBL] [Abstract][Full Text] [Related]
13. A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents.
Romagnoli R; Oliva P; Salvador MK; Manfredini S; Padroni C; Brancale A; Ferla S; Hamel E; Ronca R; Maccarinelli F; Rruga F; Mariotto E; Viola G; Bortolozzi R
Eur J Med Chem; 2021 Mar; 214():113229. PubMed ID: 33550186
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
15. An ent-Kaurane Diterpenoid Isolated from Rabdosia excisa Suppresses Bcr-Abl Protein Expression in Vitro and in Vivo and Induces Apoptosis of CML Cells.
Xia Y; Feng M; Wang E; Chen L; Wang J; Hou R; Zhao Y
Chem Biodivers; 2019 Oct; 16(10):e1900443. PubMed ID: 31468670
[TBL] [Abstract][Full Text] [Related]
16. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
[TBL] [Abstract][Full Text] [Related]
17. Discovery of an indole-substituted furanone with tubulin polymerization inhibition activity.
Mowery P; Filkorn MM; Hurysz B; Kwansare DO; Lafferty MM; McFadden MA; Neerukonda ND; Patel RR; Pierce K; Sockett KA; Truax NJ; Webster NR; Pelkey ET
Bioorg Med Chem Lett; 2021 Jun; 41():127991. PubMed ID: 33775833
[TBL] [Abstract][Full Text] [Related]
18. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and in vitro Evaluation of Tubulin-Targeting Dibenzothiazines with Antiproliferative Activity as a Novel Heterocycle Building Block.
Guerra WD; Lucena-Agell D; Hortigüela R; Rossi RA; Fernando Díaz J; Padrón JM; Barolo SM
ChemMedChem; 2021 Oct; 16(19):3003-3016. PubMed ID: 34231318
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
